The Experts below are selected from a list of 81 Experts worldwide ranked by ideXlab platform
Irwin Goldstein - One of the best experts on this subject based on the ideXlab platform.
-
intracavernous Alprostadil Alfadex edex viridal is effective and safe in patients with erectile dysfunction after failing sildenafil viagra
Urology, 2000Co-Authors: Ridwan Shabsigh, M Gittleman, J Mcmurray, Joel M. Kaufman, Harin Padmanathan, Irwin GoldsteinAbstract:Abstract Objectives. Sildenafil (Viagra), an oral treatment for erectile dysfunction, has proved popular since its introduction in 1998. However, not all patients respond to this form of therapy. Consequently, this study investigated the efficacy of intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) treatment in patients not responding to sildenafil. Methods. In an open-label, multicenter study, patients with erectile dysfunction were treated with sildenafil for 4 weeks. The initial dose was 50 mg, which was increased to 100 mg if no response was achieved. Patients not responding to treatment, measured using the International Index of Erectile Function (IIEF) questionnaire, entered an Alprostadil Alfadex in-office titration phase, to determine the optimal dose, up to 40 μg. A 6-week Alprostadil Alfadex at-home treatment phase followed. Results. In 67 patients who did not respond satisfactorily to sildenafil, the Alprostadil Alfadex at-home therapy resulted in improvements in questions 3 and 4 of the IIEF in 60 (89.6%) and 57 (85.1%) patients, respectively. The mean improvement in IIEF score for these patients was 2.75 and 2.63 for questions 3 and 4, respectively. The most common side effect was penile pain in 25 (29.4%) of 85 patients treated with Alprostadil Alfadex in-office and at home. Conclusions. Alprostadil Alfadex therapy can be used effectively and safely in men who fail initial therapy with sildenafil.
-
Intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra).
Urology, 2000Co-Authors: Ridwan Shabsigh, Harin Padma-nathan, M Gittleman, J Mcmurray, Joel M. Kaufman, Irwin GoldsteinAbstract:Abstract Objectives. Sildenafil (Viagra), an oral treatment for erectile dysfunction, has proved popular since its introduction in 1998. However, not all patients respond to this form of therapy. Consequently, this study investigated the efficacy of intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) treatment in patients not responding to sildenafil. Methods. In an open-label, multicenter study, patients with erectile dysfunction were treated with sildenafil for 4 weeks. The initial dose was 50 mg, which was increased to 100 mg if no response was achieved. Patients not responding to treatment, measured using the International Index of Erectile Function (IIEF) questionnaire, entered an Alprostadil Alfadex in-office titration phase, to determine the optimal dose, up to 40 μg. A 6-week Alprostadil Alfadex at-home treatment phase followed. Results. In 67 patients who did not respond satisfactorily to sildenafil, the Alprostadil Alfadex at-home therapy resulted in improvements in questions 3 and 4 of the IIEF in 60 (89.6%) and 57 (85.1%) patients, respectively. The mean improvement in IIEF score for these patients was 2.75 and 2.63 for questions 3 and 4, respectively. The most common side effect was penile pain in 25 (29.4%) of 85 patients treated with Alprostadil Alfadex in-office and at home. Conclusions. Alprostadil Alfadex therapy can be used effectively and safely in men who fail initial therapy with sildenafil.
-
Intracavernous Alprostadil Alfadex is more efficacious, better tolerated, and preferred over intraurethral Alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study.
Urology, 2000Co-Authors: Ridwan Shabsigh, Harin Padma-nathan, M Gittleman, J Mcmurray, Joel M. Kaufman, Irwin GoldsteinAbstract:Objectives. To compare the efficacy, safety, and patient preference of intracavernously administered Alprostadil Alfadex and intraurethrally administered Alprostadil. Methods. A crossover, randomized, open-label multicenter study of 111 patients with erectile dysfunction of at least 6 months’ duration compared the efficacy, safety, and patient preference of intracavernosal Alprostadil (EDEX/Viridal) with MUSE plus optional ACTIS. All patients underwent an in-office dose titration with either drug before undertaking an at-home treatment phase. The most frequently used doses during the at-home phase were 40 μg (44.1% of men) and 1000 μg (86.8% of men) for EDEX and MUSE, respectively; the mean doses were 26.1 μg and 922.5 μg for EDEX and MUSE, respectively. Results. More EDEX than MUSE administrations resulted in an erection sufficient for sexual intercourse (82.5% versus 53.0%); significantly more patients using EDEX achieved at least one erection sufficient for sexual intercourse (92.6% versus 61.8%; P
-
intracavernous Alprostadil Alfadex is more efficacious better tolerated and preferred over intraurethral Alprostadil plus optional actis a comparative randomized crossover multicenter study
Urology, 2000Co-Authors: Ridwan Shabsigh, M Gittleman, J Mcmurray, Joel M. Kaufman, Harin Padmanathan, Irwin GoldsteinAbstract:Objectives. To compare the efficacy, safety, and patient preference of intracavernously administered Alprostadil Alfadex and intraurethrally administered Alprostadil. Methods. A crossover, randomized, open-label multicenter study of 111 patients with erectile dysfunction of at least 6 months’ duration compared the efficacy, safety, and patient preference of intracavernosal Alprostadil (EDEX/Viridal) with MUSE plus optional ACTIS. All patients underwent an in-office dose titration with either drug before undertaking an at-home treatment phase. The most frequently used doses during the at-home phase were 40 μg (44.1% of men) and 1000 μg (86.8% of men) for EDEX and MUSE, respectively; the mean doses were 26.1 μg and 922.5 μg for EDEX and MUSE, respectively. Results. More EDEX than MUSE administrations resulted in an erection sufficient for sexual intercourse (82.5% versus 53.0%); significantly more patients using EDEX achieved at least one erection sufficient for sexual intercourse (92.6% versus 61.8%; P <0.0001); and EDEX use resulted in a significantly greater percentage of patients attaining at least 75% of erections sufficient for sexual intercourse (75% versus 36.8%; P <0.0001). Penile pain was the most common side effect for both medications: 20.0% versus 30.5% (in-office) and 33.8% versus 25.0% (at-home) for EDEX and MUSE, respectively. Similar numbers of adverse events were reported with either treatment during the at-home phase. Patient and partner satisfaction was greater with EDEX, and more patients preferred this therapy, choosing to continue it during a patient preference period at the end of the study. Conclusions. Since intracavernous injection therapy was more efficacious, better tolerated, and preferred by the patients and their partners, it should be offered as the first-choice treatment if oral therapy fails or is contraindicated.
Ridwan Shabsigh - One of the best experts on this subject based on the ideXlab platform.
-
intracavernous Alprostadil Alfadex edex viridal is effective and safe in patients with erectile dysfunction after failing sildenafil viagra
Urology, 2000Co-Authors: Ridwan Shabsigh, M Gittleman, J Mcmurray, Joel M. Kaufman, Harin Padmanathan, Irwin GoldsteinAbstract:Abstract Objectives. Sildenafil (Viagra), an oral treatment for erectile dysfunction, has proved popular since its introduction in 1998. However, not all patients respond to this form of therapy. Consequently, this study investigated the efficacy of intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) treatment in patients not responding to sildenafil. Methods. In an open-label, multicenter study, patients with erectile dysfunction were treated with sildenafil for 4 weeks. The initial dose was 50 mg, which was increased to 100 mg if no response was achieved. Patients not responding to treatment, measured using the International Index of Erectile Function (IIEF) questionnaire, entered an Alprostadil Alfadex in-office titration phase, to determine the optimal dose, up to 40 μg. A 6-week Alprostadil Alfadex at-home treatment phase followed. Results. In 67 patients who did not respond satisfactorily to sildenafil, the Alprostadil Alfadex at-home therapy resulted in improvements in questions 3 and 4 of the IIEF in 60 (89.6%) and 57 (85.1%) patients, respectively. The mean improvement in IIEF score for these patients was 2.75 and 2.63 for questions 3 and 4, respectively. The most common side effect was penile pain in 25 (29.4%) of 85 patients treated with Alprostadil Alfadex in-office and at home. Conclusions. Alprostadil Alfadex therapy can be used effectively and safely in men who fail initial therapy with sildenafil.
-
Intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra).
Urology, 2000Co-Authors: Ridwan Shabsigh, Harin Padma-nathan, M Gittleman, J Mcmurray, Joel M. Kaufman, Irwin GoldsteinAbstract:Abstract Objectives. Sildenafil (Viagra), an oral treatment for erectile dysfunction, has proved popular since its introduction in 1998. However, not all patients respond to this form of therapy. Consequently, this study investigated the efficacy of intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) treatment in patients not responding to sildenafil. Methods. In an open-label, multicenter study, patients with erectile dysfunction were treated with sildenafil for 4 weeks. The initial dose was 50 mg, which was increased to 100 mg if no response was achieved. Patients not responding to treatment, measured using the International Index of Erectile Function (IIEF) questionnaire, entered an Alprostadil Alfadex in-office titration phase, to determine the optimal dose, up to 40 μg. A 6-week Alprostadil Alfadex at-home treatment phase followed. Results. In 67 patients who did not respond satisfactorily to sildenafil, the Alprostadil Alfadex at-home therapy resulted in improvements in questions 3 and 4 of the IIEF in 60 (89.6%) and 57 (85.1%) patients, respectively. The mean improvement in IIEF score for these patients was 2.75 and 2.63 for questions 3 and 4, respectively. The most common side effect was penile pain in 25 (29.4%) of 85 patients treated with Alprostadil Alfadex in-office and at home. Conclusions. Alprostadil Alfadex therapy can be used effectively and safely in men who fail initial therapy with sildenafil.
-
Intracavernous Alprostadil Alfadex is more efficacious, better tolerated, and preferred over intraurethral Alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study.
Urology, 2000Co-Authors: Ridwan Shabsigh, Harin Padma-nathan, M Gittleman, J Mcmurray, Joel M. Kaufman, Irwin GoldsteinAbstract:Objectives. To compare the efficacy, safety, and patient preference of intracavernously administered Alprostadil Alfadex and intraurethrally administered Alprostadil. Methods. A crossover, randomized, open-label multicenter study of 111 patients with erectile dysfunction of at least 6 months’ duration compared the efficacy, safety, and patient preference of intracavernosal Alprostadil (EDEX/Viridal) with MUSE plus optional ACTIS. All patients underwent an in-office dose titration with either drug before undertaking an at-home treatment phase. The most frequently used doses during the at-home phase were 40 μg (44.1% of men) and 1000 μg (86.8% of men) for EDEX and MUSE, respectively; the mean doses were 26.1 μg and 922.5 μg for EDEX and MUSE, respectively. Results. More EDEX than MUSE administrations resulted in an erection sufficient for sexual intercourse (82.5% versus 53.0%); significantly more patients using EDEX achieved at least one erection sufficient for sexual intercourse (92.6% versus 61.8%; P
-
intracavernous Alprostadil Alfadex is more efficacious better tolerated and preferred over intraurethral Alprostadil plus optional actis a comparative randomized crossover multicenter study
Urology, 2000Co-Authors: Ridwan Shabsigh, M Gittleman, J Mcmurray, Joel M. Kaufman, Harin Padmanathan, Irwin GoldsteinAbstract:Objectives. To compare the efficacy, safety, and patient preference of intracavernously administered Alprostadil Alfadex and intraurethrally administered Alprostadil. Methods. A crossover, randomized, open-label multicenter study of 111 patients with erectile dysfunction of at least 6 months’ duration compared the efficacy, safety, and patient preference of intracavernosal Alprostadil (EDEX/Viridal) with MUSE plus optional ACTIS. All patients underwent an in-office dose titration with either drug before undertaking an at-home treatment phase. The most frequently used doses during the at-home phase were 40 μg (44.1% of men) and 1000 μg (86.8% of men) for EDEX and MUSE, respectively; the mean doses were 26.1 μg and 922.5 μg for EDEX and MUSE, respectively. Results. More EDEX than MUSE administrations resulted in an erection sufficient for sexual intercourse (82.5% versus 53.0%); significantly more patients using EDEX achieved at least one erection sufficient for sexual intercourse (92.6% versus 61.8%; P <0.0001); and EDEX use resulted in a significantly greater percentage of patients attaining at least 75% of erections sufficient for sexual intercourse (75% versus 36.8%; P <0.0001). Penile pain was the most common side effect for both medications: 20.0% versus 30.5% (in-office) and 33.8% versus 25.0% (at-home) for EDEX and MUSE, respectively. Similar numbers of adverse events were reported with either treatment during the at-home phase. Patient and partner satisfaction was greater with EDEX, and more patients preferred this therapy, choosing to continue it during a patient preference period at the end of the study. Conclusions. Since intracavernous injection therapy was more efficacious, better tolerated, and preferred by the patients and their partners, it should be offered as the first-choice treatment if oral therapy fails or is contraindicated.
M Gittleman - One of the best experts on this subject based on the ideXlab platform.
-
intracavernous Alprostadil Alfadex edex viridal is effective and safe in patients with erectile dysfunction after failing sildenafil viagra
Urology, 2000Co-Authors: Ridwan Shabsigh, M Gittleman, J Mcmurray, Joel M. Kaufman, Harin Padmanathan, Irwin GoldsteinAbstract:Abstract Objectives. Sildenafil (Viagra), an oral treatment for erectile dysfunction, has proved popular since its introduction in 1998. However, not all patients respond to this form of therapy. Consequently, this study investigated the efficacy of intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) treatment in patients not responding to sildenafil. Methods. In an open-label, multicenter study, patients with erectile dysfunction were treated with sildenafil for 4 weeks. The initial dose was 50 mg, which was increased to 100 mg if no response was achieved. Patients not responding to treatment, measured using the International Index of Erectile Function (IIEF) questionnaire, entered an Alprostadil Alfadex in-office titration phase, to determine the optimal dose, up to 40 μg. A 6-week Alprostadil Alfadex at-home treatment phase followed. Results. In 67 patients who did not respond satisfactorily to sildenafil, the Alprostadil Alfadex at-home therapy resulted in improvements in questions 3 and 4 of the IIEF in 60 (89.6%) and 57 (85.1%) patients, respectively. The mean improvement in IIEF score for these patients was 2.75 and 2.63 for questions 3 and 4, respectively. The most common side effect was penile pain in 25 (29.4%) of 85 patients treated with Alprostadil Alfadex in-office and at home. Conclusions. Alprostadil Alfadex therapy can be used effectively and safely in men who fail initial therapy with sildenafil.
-
Intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra).
Urology, 2000Co-Authors: Ridwan Shabsigh, Harin Padma-nathan, M Gittleman, J Mcmurray, Joel M. Kaufman, Irwin GoldsteinAbstract:Abstract Objectives. Sildenafil (Viagra), an oral treatment for erectile dysfunction, has proved popular since its introduction in 1998. However, not all patients respond to this form of therapy. Consequently, this study investigated the efficacy of intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) treatment in patients not responding to sildenafil. Methods. In an open-label, multicenter study, patients with erectile dysfunction were treated with sildenafil for 4 weeks. The initial dose was 50 mg, which was increased to 100 mg if no response was achieved. Patients not responding to treatment, measured using the International Index of Erectile Function (IIEF) questionnaire, entered an Alprostadil Alfadex in-office titration phase, to determine the optimal dose, up to 40 μg. A 6-week Alprostadil Alfadex at-home treatment phase followed. Results. In 67 patients who did not respond satisfactorily to sildenafil, the Alprostadil Alfadex at-home therapy resulted in improvements in questions 3 and 4 of the IIEF in 60 (89.6%) and 57 (85.1%) patients, respectively. The mean improvement in IIEF score for these patients was 2.75 and 2.63 for questions 3 and 4, respectively. The most common side effect was penile pain in 25 (29.4%) of 85 patients treated with Alprostadil Alfadex in-office and at home. Conclusions. Alprostadil Alfadex therapy can be used effectively and safely in men who fail initial therapy with sildenafil.
-
Intracavernous Alprostadil Alfadex is more efficacious, better tolerated, and preferred over intraurethral Alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study.
Urology, 2000Co-Authors: Ridwan Shabsigh, Harin Padma-nathan, M Gittleman, J Mcmurray, Joel M. Kaufman, Irwin GoldsteinAbstract:Objectives. To compare the efficacy, safety, and patient preference of intracavernously administered Alprostadil Alfadex and intraurethrally administered Alprostadil. Methods. A crossover, randomized, open-label multicenter study of 111 patients with erectile dysfunction of at least 6 months’ duration compared the efficacy, safety, and patient preference of intracavernosal Alprostadil (EDEX/Viridal) with MUSE plus optional ACTIS. All patients underwent an in-office dose titration with either drug before undertaking an at-home treatment phase. The most frequently used doses during the at-home phase were 40 μg (44.1% of men) and 1000 μg (86.8% of men) for EDEX and MUSE, respectively; the mean doses were 26.1 μg and 922.5 μg for EDEX and MUSE, respectively. Results. More EDEX than MUSE administrations resulted in an erection sufficient for sexual intercourse (82.5% versus 53.0%); significantly more patients using EDEX achieved at least one erection sufficient for sexual intercourse (92.6% versus 61.8%; P
-
intracavernous Alprostadil Alfadex is more efficacious better tolerated and preferred over intraurethral Alprostadil plus optional actis a comparative randomized crossover multicenter study
Urology, 2000Co-Authors: Ridwan Shabsigh, M Gittleman, J Mcmurray, Joel M. Kaufman, Harin Padmanathan, Irwin GoldsteinAbstract:Objectives. To compare the efficacy, safety, and patient preference of intracavernously administered Alprostadil Alfadex and intraurethrally administered Alprostadil. Methods. A crossover, randomized, open-label multicenter study of 111 patients with erectile dysfunction of at least 6 months’ duration compared the efficacy, safety, and patient preference of intracavernosal Alprostadil (EDEX/Viridal) with MUSE plus optional ACTIS. All patients underwent an in-office dose titration with either drug before undertaking an at-home treatment phase. The most frequently used doses during the at-home phase were 40 μg (44.1% of men) and 1000 μg (86.8% of men) for EDEX and MUSE, respectively; the mean doses were 26.1 μg and 922.5 μg for EDEX and MUSE, respectively. Results. More EDEX than MUSE administrations resulted in an erection sufficient for sexual intercourse (82.5% versus 53.0%); significantly more patients using EDEX achieved at least one erection sufficient for sexual intercourse (92.6% versus 61.8%; P <0.0001); and EDEX use resulted in a significantly greater percentage of patients attaining at least 75% of erections sufficient for sexual intercourse (75% versus 36.8%; P <0.0001). Penile pain was the most common side effect for both medications: 20.0% versus 30.5% (in-office) and 33.8% versus 25.0% (at-home) for EDEX and MUSE, respectively. Similar numbers of adverse events were reported with either treatment during the at-home phase. Patient and partner satisfaction was greater with EDEX, and more patients preferred this therapy, choosing to continue it during a patient preference period at the end of the study. Conclusions. Since intracavernous injection therapy was more efficacious, better tolerated, and preferred by the patients and their partners, it should be offered as the first-choice treatment if oral therapy fails or is contraindicated.
J Mcmurray - One of the best experts on this subject based on the ideXlab platform.
-
intracavernous Alprostadil Alfadex edex viridal is effective and safe in patients with erectile dysfunction after failing sildenafil viagra
Urology, 2000Co-Authors: Ridwan Shabsigh, M Gittleman, J Mcmurray, Joel M. Kaufman, Harin Padmanathan, Irwin GoldsteinAbstract:Abstract Objectives. Sildenafil (Viagra), an oral treatment for erectile dysfunction, has proved popular since its introduction in 1998. However, not all patients respond to this form of therapy. Consequently, this study investigated the efficacy of intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) treatment in patients not responding to sildenafil. Methods. In an open-label, multicenter study, patients with erectile dysfunction were treated with sildenafil for 4 weeks. The initial dose was 50 mg, which was increased to 100 mg if no response was achieved. Patients not responding to treatment, measured using the International Index of Erectile Function (IIEF) questionnaire, entered an Alprostadil Alfadex in-office titration phase, to determine the optimal dose, up to 40 μg. A 6-week Alprostadil Alfadex at-home treatment phase followed. Results. In 67 patients who did not respond satisfactorily to sildenafil, the Alprostadil Alfadex at-home therapy resulted in improvements in questions 3 and 4 of the IIEF in 60 (89.6%) and 57 (85.1%) patients, respectively. The mean improvement in IIEF score for these patients was 2.75 and 2.63 for questions 3 and 4, respectively. The most common side effect was penile pain in 25 (29.4%) of 85 patients treated with Alprostadil Alfadex in-office and at home. Conclusions. Alprostadil Alfadex therapy can be used effectively and safely in men who fail initial therapy with sildenafil.
-
Intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra).
Urology, 2000Co-Authors: Ridwan Shabsigh, Harin Padma-nathan, M Gittleman, J Mcmurray, Joel M. Kaufman, Irwin GoldsteinAbstract:Abstract Objectives. Sildenafil (Viagra), an oral treatment for erectile dysfunction, has proved popular since its introduction in 1998. However, not all patients respond to this form of therapy. Consequently, this study investigated the efficacy of intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) treatment in patients not responding to sildenafil. Methods. In an open-label, multicenter study, patients with erectile dysfunction were treated with sildenafil for 4 weeks. The initial dose was 50 mg, which was increased to 100 mg if no response was achieved. Patients not responding to treatment, measured using the International Index of Erectile Function (IIEF) questionnaire, entered an Alprostadil Alfadex in-office titration phase, to determine the optimal dose, up to 40 μg. A 6-week Alprostadil Alfadex at-home treatment phase followed. Results. In 67 patients who did not respond satisfactorily to sildenafil, the Alprostadil Alfadex at-home therapy resulted in improvements in questions 3 and 4 of the IIEF in 60 (89.6%) and 57 (85.1%) patients, respectively. The mean improvement in IIEF score for these patients was 2.75 and 2.63 for questions 3 and 4, respectively. The most common side effect was penile pain in 25 (29.4%) of 85 patients treated with Alprostadil Alfadex in-office and at home. Conclusions. Alprostadil Alfadex therapy can be used effectively and safely in men who fail initial therapy with sildenafil.
-
Intracavernous Alprostadil Alfadex is more efficacious, better tolerated, and preferred over intraurethral Alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study.
Urology, 2000Co-Authors: Ridwan Shabsigh, Harin Padma-nathan, M Gittleman, J Mcmurray, Joel M. Kaufman, Irwin GoldsteinAbstract:Objectives. To compare the efficacy, safety, and patient preference of intracavernously administered Alprostadil Alfadex and intraurethrally administered Alprostadil. Methods. A crossover, randomized, open-label multicenter study of 111 patients with erectile dysfunction of at least 6 months’ duration compared the efficacy, safety, and patient preference of intracavernosal Alprostadil (EDEX/Viridal) with MUSE plus optional ACTIS. All patients underwent an in-office dose titration with either drug before undertaking an at-home treatment phase. The most frequently used doses during the at-home phase were 40 μg (44.1% of men) and 1000 μg (86.8% of men) for EDEX and MUSE, respectively; the mean doses were 26.1 μg and 922.5 μg for EDEX and MUSE, respectively. Results. More EDEX than MUSE administrations resulted in an erection sufficient for sexual intercourse (82.5% versus 53.0%); significantly more patients using EDEX achieved at least one erection sufficient for sexual intercourse (92.6% versus 61.8%; P
-
intracavernous Alprostadil Alfadex is more efficacious better tolerated and preferred over intraurethral Alprostadil plus optional actis a comparative randomized crossover multicenter study
Urology, 2000Co-Authors: Ridwan Shabsigh, M Gittleman, J Mcmurray, Joel M. Kaufman, Harin Padmanathan, Irwin GoldsteinAbstract:Objectives. To compare the efficacy, safety, and patient preference of intracavernously administered Alprostadil Alfadex and intraurethrally administered Alprostadil. Methods. A crossover, randomized, open-label multicenter study of 111 patients with erectile dysfunction of at least 6 months’ duration compared the efficacy, safety, and patient preference of intracavernosal Alprostadil (EDEX/Viridal) with MUSE plus optional ACTIS. All patients underwent an in-office dose titration with either drug before undertaking an at-home treatment phase. The most frequently used doses during the at-home phase were 40 μg (44.1% of men) and 1000 μg (86.8% of men) for EDEX and MUSE, respectively; the mean doses were 26.1 μg and 922.5 μg for EDEX and MUSE, respectively. Results. More EDEX than MUSE administrations resulted in an erection sufficient for sexual intercourse (82.5% versus 53.0%); significantly more patients using EDEX achieved at least one erection sufficient for sexual intercourse (92.6% versus 61.8%; P <0.0001); and EDEX use resulted in a significantly greater percentage of patients attaining at least 75% of erections sufficient for sexual intercourse (75% versus 36.8%; P <0.0001). Penile pain was the most common side effect for both medications: 20.0% versus 30.5% (in-office) and 33.8% versus 25.0% (at-home) for EDEX and MUSE, respectively. Similar numbers of adverse events were reported with either treatment during the at-home phase. Patient and partner satisfaction was greater with EDEX, and more patients preferred this therapy, choosing to continue it during a patient preference period at the end of the study. Conclusions. Since intracavernous injection therapy was more efficacious, better tolerated, and preferred by the patients and their partners, it should be offered as the first-choice treatment if oral therapy fails or is contraindicated.
Joel M. Kaufman - One of the best experts on this subject based on the ideXlab platform.
-
intracavernous Alprostadil Alfadex edex viridal is effective and safe in patients with erectile dysfunction after failing sildenafil viagra
Urology, 2000Co-Authors: Ridwan Shabsigh, M Gittleman, J Mcmurray, Joel M. Kaufman, Harin Padmanathan, Irwin GoldsteinAbstract:Abstract Objectives. Sildenafil (Viagra), an oral treatment for erectile dysfunction, has proved popular since its introduction in 1998. However, not all patients respond to this form of therapy. Consequently, this study investigated the efficacy of intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) treatment in patients not responding to sildenafil. Methods. In an open-label, multicenter study, patients with erectile dysfunction were treated with sildenafil for 4 weeks. The initial dose was 50 mg, which was increased to 100 mg if no response was achieved. Patients not responding to treatment, measured using the International Index of Erectile Function (IIEF) questionnaire, entered an Alprostadil Alfadex in-office titration phase, to determine the optimal dose, up to 40 μg. A 6-week Alprostadil Alfadex at-home treatment phase followed. Results. In 67 patients who did not respond satisfactorily to sildenafil, the Alprostadil Alfadex at-home therapy resulted in improvements in questions 3 and 4 of the IIEF in 60 (89.6%) and 57 (85.1%) patients, respectively. The mean improvement in IIEF score for these patients was 2.75 and 2.63 for questions 3 and 4, respectively. The most common side effect was penile pain in 25 (29.4%) of 85 patients treated with Alprostadil Alfadex in-office and at home. Conclusions. Alprostadil Alfadex therapy can be used effectively and safely in men who fail initial therapy with sildenafil.
-
Intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra).
Urology, 2000Co-Authors: Ridwan Shabsigh, Harin Padma-nathan, M Gittleman, J Mcmurray, Joel M. Kaufman, Irwin GoldsteinAbstract:Abstract Objectives. Sildenafil (Viagra), an oral treatment for erectile dysfunction, has proved popular since its introduction in 1998. However, not all patients respond to this form of therapy. Consequently, this study investigated the efficacy of intracavernous Alprostadil Alfadex (EDEX/VIRIDAL) treatment in patients not responding to sildenafil. Methods. In an open-label, multicenter study, patients with erectile dysfunction were treated with sildenafil for 4 weeks. The initial dose was 50 mg, which was increased to 100 mg if no response was achieved. Patients not responding to treatment, measured using the International Index of Erectile Function (IIEF) questionnaire, entered an Alprostadil Alfadex in-office titration phase, to determine the optimal dose, up to 40 μg. A 6-week Alprostadil Alfadex at-home treatment phase followed. Results. In 67 patients who did not respond satisfactorily to sildenafil, the Alprostadil Alfadex at-home therapy resulted in improvements in questions 3 and 4 of the IIEF in 60 (89.6%) and 57 (85.1%) patients, respectively. The mean improvement in IIEF score for these patients was 2.75 and 2.63 for questions 3 and 4, respectively. The most common side effect was penile pain in 25 (29.4%) of 85 patients treated with Alprostadil Alfadex in-office and at home. Conclusions. Alprostadil Alfadex therapy can be used effectively and safely in men who fail initial therapy with sildenafil.
-
Intracavernous Alprostadil Alfadex is more efficacious, better tolerated, and preferred over intraurethral Alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study.
Urology, 2000Co-Authors: Ridwan Shabsigh, Harin Padma-nathan, M Gittleman, J Mcmurray, Joel M. Kaufman, Irwin GoldsteinAbstract:Objectives. To compare the efficacy, safety, and patient preference of intracavernously administered Alprostadil Alfadex and intraurethrally administered Alprostadil. Methods. A crossover, randomized, open-label multicenter study of 111 patients with erectile dysfunction of at least 6 months’ duration compared the efficacy, safety, and patient preference of intracavernosal Alprostadil (EDEX/Viridal) with MUSE plus optional ACTIS. All patients underwent an in-office dose titration with either drug before undertaking an at-home treatment phase. The most frequently used doses during the at-home phase were 40 μg (44.1% of men) and 1000 μg (86.8% of men) for EDEX and MUSE, respectively; the mean doses were 26.1 μg and 922.5 μg for EDEX and MUSE, respectively. Results. More EDEX than MUSE administrations resulted in an erection sufficient for sexual intercourse (82.5% versus 53.0%); significantly more patients using EDEX achieved at least one erection sufficient for sexual intercourse (92.6% versus 61.8%; P
-
intracavernous Alprostadil Alfadex is more efficacious better tolerated and preferred over intraurethral Alprostadil plus optional actis a comparative randomized crossover multicenter study
Urology, 2000Co-Authors: Ridwan Shabsigh, M Gittleman, J Mcmurray, Joel M. Kaufman, Harin Padmanathan, Irwin GoldsteinAbstract:Objectives. To compare the efficacy, safety, and patient preference of intracavernously administered Alprostadil Alfadex and intraurethrally administered Alprostadil. Methods. A crossover, randomized, open-label multicenter study of 111 patients with erectile dysfunction of at least 6 months’ duration compared the efficacy, safety, and patient preference of intracavernosal Alprostadil (EDEX/Viridal) with MUSE plus optional ACTIS. All patients underwent an in-office dose titration with either drug before undertaking an at-home treatment phase. The most frequently used doses during the at-home phase were 40 μg (44.1% of men) and 1000 μg (86.8% of men) for EDEX and MUSE, respectively; the mean doses were 26.1 μg and 922.5 μg for EDEX and MUSE, respectively. Results. More EDEX than MUSE administrations resulted in an erection sufficient for sexual intercourse (82.5% versus 53.0%); significantly more patients using EDEX achieved at least one erection sufficient for sexual intercourse (92.6% versus 61.8%; P <0.0001); and EDEX use resulted in a significantly greater percentage of patients attaining at least 75% of erections sufficient for sexual intercourse (75% versus 36.8%; P <0.0001). Penile pain was the most common side effect for both medications: 20.0% versus 30.5% (in-office) and 33.8% versus 25.0% (at-home) for EDEX and MUSE, respectively. Similar numbers of adverse events were reported with either treatment during the at-home phase. Patient and partner satisfaction was greater with EDEX, and more patients preferred this therapy, choosing to continue it during a patient preference period at the end of the study. Conclusions. Since intracavernous injection therapy was more efficacious, better tolerated, and preferred by the patients and their partners, it should be offered as the first-choice treatment if oral therapy fails or is contraindicated.